Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Work In Process (2019 - 2025)

Pulmonx (LUNG) has disclosed Work In Process for 7 consecutive years, with $577000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Work In Process rose 56.37% to $577000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $577000.0, a 56.37% increase, with the full-year FY2024 number at $457000.0, up 7.03% from a year prior.
  • Work In Process was $577000.0 for Q3 2025 at Pulmonx, up from $562000.0 in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $784000.0 in Q2 2022 to a low of $313000.0 in Q1 2021.
  • A 5-year average of $513842.1 and a median of $503000.0 in 2025 define the central range for Work In Process.
  • Peak YoY movement for Work In Process: skyrocketed 139.62% in 2022, then plummeted 39.15% in 2024.
  • Pulmonx's Work In Process stood at $518000.0 in 2021, then fell by 25.48% to $386000.0 in 2022, then rose by 10.62% to $427000.0 in 2023, then rose by 7.03% to $457000.0 in 2024, then grew by 26.26% to $577000.0 in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Work In Process are $577000.0 (Q3 2025), $562000.0 (Q2 2025), and $503000.0 (Q1 2025).